NCT03304873View on ClinicalTrials.gov

Retapamulin as a Decolonizing Agent for MRSA

PHASE3CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

February 13, 2019

Study Completion Date

March 18, 2019

Conditions
MRSA
Interventions
DRUG

Retapamulin

Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).

DRUG

Placebo Ointment

The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.

Trial Locations (1)

10016

New York University School of Medicine, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03304873 - Retapamulin as a Decolonizing Agent for MRSA | Biotech Hunter | Biotech Hunter